A phase II trial was performed to evaluate the efficacy and safety of gefitinib in patients with persistent/recurrent endometrial cancer.
Keywords: Gefitinib; endometrial cancer; epidermal growth factor receptor (EGFR); soluble EGFR; estrogen receptor; progesterone receptor
How to Cite:
Leslie, K. K., (2013) “A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study*”, Proceedings in Obstetrics and Gynecology 3(4), 1-2. doi: https://doi.org/10.17077/2154-4751.1226
Rights: Copyright © Kimberly K. Leslie, Michael W. Sill, Edgar Fischer, Kathleen M. Darcy, Robet S. Mannel, Krishnansu S. Tewari, Parviz Hanjan, Jason A. Wilken, Andre T. Baron, Andrew K. Godwin, Russell J. Schilder, Meenakshi Singh, Nita J. Maihle, 2013.